Biocon Pharma receives USFDA approval for daptomycin
The approval further adds to Biocon’s portfolio of complex drug products
The approval further adds to Biocon’s portfolio of complex drug products
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Also received tentative approval for 137 mg
Subscribe To Our Newsletter & Stay Updated